| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 499 | 243 | 13 |
| Full Text Views | 9 | 4 | 0 |
| PDF Downloads | 7 | 5 | 0 |
Cycloguanil Pamoate (CI-501) as a Causal Prophylactic against a Southern Rhodesian Strain of Falciparum Malaria
Joseph S. Lunn
Joseph S. Lunn
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, Malaria Project, U. S. Penitentiary, Atlanta, Georgia
Search for other papers by Joseph S. Lunn in
Current site
Google Scholar
PubMed
Search for other papers by Joseph S. Lunn in
Current site
Google Scholar
PubMed
William Chin
William Chin
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, Malaria Project, U. S. Penitentiary, Atlanta, Georgia
Search for other papers by William Chin in
Current site
Google Scholar
PubMed
Search for other papers by William Chin in
Current site
Google Scholar
PubMed
Peter G. Contacos
Peter G. Contacos
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, Malaria Project, U. S. Penitentiary, Atlanta, Georgia
Search for other papers by Peter G. Contacos in
Current site
Google Scholar
PubMed
Search for other papers by Peter G. Contacos in
Current site
Google Scholar
PubMed
G. Robert Coatney
G. Robert Coatney
Laboratory of Parasite Chemotherapy, National Institute of Allergy and Infectious Diseases, Malaria Project, U. S. Penitentiary, Atlanta, Georgia
Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Search for other papers by G. Robert Coatney in
Current site
Google Scholar
PubMed
Summary and Conclusions
Cycloguanil pamoate, known as CI-501 (Camolar), given as a single intramuscular injection at a dose of 5 mg (base) per kg body weight, was used to determine if the drug acted as a causal prophylactic against a Southern Rhodesian strain of falciparum malaria. A total of 21 prisoner volunteers participated in the study.
Nine volunteers were medicated at intervals ranging from one day before to nine days after exposure to falciparum malaria by the bites of heavily infected Anopheles freeborni mosquitoes. Seven volunteers were used as subinoculees to prove whether or not four of the study cases had subpatent infections. Five volunteers served as controls.
None of the volunteers medicated through the 5th day after exposure developed malaria. The volunteer medicated on the 7th post-exposure day developed a subpatent infection as determined by subinoculation. The man who received his medication on the 9th post-exposure day developed a patent infection; he exhibited a modified clinical attack with low parasitemia.
These results indicate that CI-501 acts as a true causal prophylactic against this strain of falciparum malaria despite the fact that the erythrocytic stages are partially resistant to it.
Author Notes
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 499 | 243 | 13 |
| Full Text Views | 9 | 4 | 0 |
| PDF Downloads | 7 | 5 | 0 |